The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.
COVID-19
Communicable Disease Control
/ methods
Coronavirus Infections
/ epidemiology
Delivery of Health Care
/ ethics
Humans
Mental Health
/ standards
Organizational Innovation
Pandemics
/ prevention & control
Pneumonia, Viral
/ epidemiology
Practice Patterns, Physicians'
/ organization & administration
Telemedicine
/ methods
Urogenital Neoplasms
/ psychology
Biomedical research
Health services accessibility
Mental health
Pandemic
Telemedicine
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
29
06
2020
accepted:
20
08
2020
pubmed:
8
9
2020
medline:
28
10
2020
entrez:
7
9
2020
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic necessitated rapid changes in medical practice. Many of these changes may add value to care, creating opportunities going forward. To provide an evidence-informed, expert-derived review of genitourinary cancer care moving forward following the initial COVID-19 pandemic. A collaborative narrative review was conducted using literature published through May 2020 (PubMed), which comprised three main topics: reduced in-person interactions arguing for increasing virtual and image-based care, optimisation of the delivery of care, and the effect of COVID-19 in health care facilities on decision-making by patients and their families. Patterns of care will evolve following the COVID-19 pandemic. Telemedicine, virtual care, and telemonitoring will increase and could offer broader access to multidisciplinary expertise without increasing costs. Comprehensive and integrative telehealth solutions will be necessary, and should consider patients' mental health and access differences due to socioeconomic status. Investigations and treatments will need to maximise efficiency and minimise health care interactions. Solutions such as one stop clinics, day case surgery, hypofractionated radiotherapy, and oral or less frequent drug dosing will be preferred. The pandemic necessitated a triage of those patients whose treatment should be expedited, delayed, or avoided, and may persist with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in circulation. Patients whose demographic characteristics are at the highest risk of complications from COVID-19 may re-evaluate the benefit of intervention for less aggressive cancers. Clinical research will need to accommodate virtual care and trial participation. Research dissemination and medical education will increasingly utilise virtual platforms, limiting in-person professional engagement; ensure data dissemination; and aim to enhance patient engagement. The COVID-19 pandemic will have lasting effects on the delivery of health care. These changes offer opportunities to improve access, delivery, and the value of care for patients with genitourinary cancers but raise concerns that physicians and health administrators must consider in order to ensure equitable access to care. The coronavirus disease 2019 (COVID-19) pandemic has dramatically changed the care provided to many patients with genitourinary cancers. This has necessitated a transition to telemedicine, changes in threshold or delays in many treatments, and an opportunity to reimagine patient care to maintain safety and improve value moving forward.
Identifiants
pubmed: 32893062
pii: S0302-2838(20)30676-X
doi: 10.1016/j.eururo.2020.08.030
pmc: PMC7471715
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
731-742Subventions
Organisme : NCI NIH HHS
ID : R37 CA222885
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA242559
Pays : United States
Informations de copyright
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Références
Eur Urol. 2019 May;75(5):881-882
pubmed: 30711329
J Shoulder Elbow Surg. 2020 Apr;29(4):775-783
pubmed: 32197766
Pract Radiat Oncol. 2017 Jul - Aug;7(4):270-278
pubmed: 28673554
J Clin Oncol. 2019 May 20;37(15):1326-1335
pubmed: 30925126
Cancer. 2009 Sep 1;115(17):3868-78
pubmed: 19637245
J Multidiscip Healthc. 2018 Jan 19;11:49-61
pubmed: 29403284
J Clin Oncol. 2016 Jun 20;34(18):2182-90
pubmed: 26884580
Eur Urol Oncol. 2019 Jul;2(4):425-428
pubmed: 31277778
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
J Arthroplasty. 2018 Apr;33(4):988-996.e4
pubmed: 29229238
J Med Internet Res. 2019 Jun 17;21(6):e13166
pubmed: 31210136
Issues Ment Health Nurs. 2019 Mar;40(3):233-239
pubmed: 30508400
Br J Cancer. 2013 Apr 16;108(7):1534-40
pubmed: 23481180
Ann Transl Med. 2019 Sep;7(17):417
pubmed: 31660316
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Eur Urol. 2020 Dec;78(6):812-819
pubmed: 32654801
BJU Int. 2005 May;95(7):969-71
pubmed: 15839915
Health Policy. 2005 May;72(2):141-8
pubmed: 15802149
Telemed J E Health. 2015 Feb;21(2):81-5
pubmed: 25474190
J Urol. 2018 Jan;199(1):89-97
pubmed: 28754540
Injury. 2020 May;51 Suppl 2:S97-S105
pubmed: 31761422
J Urol. 2018 Mar;199(3):669-675
pubmed: 28882404
Eur Urol. 2019 Jan;75(1):3-7
pubmed: 30241972
Cochrane Database Syst Rev. 2001;(3):CD000356
pubmed: 11686958
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Eur Urol. 2020 Jul;78(1):6-8
pubmed: 32376133
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Ann Oncol. 2020 Aug;31(8):1065-1074
pubmed: 32442581
Eur Urol Focus. 2018 Sep;4(5):711-717
pubmed: 28753778
Eur Urol. 2020 Jun;77(6):663-666
pubmed: 32279903
Eur Urol. 2020 Jun;77(6):667-668
pubmed: 32312544
Urology. 2019 Dec;134:154-162
pubmed: 31487512
Eur Urol. 2020 Jul;78(1):16-20
pubmed: 32362498
J Clin Oncol. 2012 Sep 1;30(25):3071-6
pubmed: 22851571
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
J Affect Disord. 2012 Dec 10;141(2-3):343-51
pubmed: 22727334
Ann Fam Med. 2018 Mar;16(2):149-154
pubmed: 29531107
BMJ Open. 2015 May 22;5(5):e006674
pubmed: 26002689
J Am Geriatr Soc. 2018 Jul;66(7):1392-1398
pubmed: 29676782
Eur J Cancer. 2006 Jan;42(2):165-70
pubmed: 16326098
BJU Int. 2020 Apr;125(4):497-505
pubmed: 31950596
World J Urol. 2020 Oct;38(10):2377-2384
pubmed: 31352565
JCO Clin Cancer Inform. 2017 Nov;1:1-10
pubmed: 30657386
BMJ Open. 2014 Jan 29;4(1):e004295
pubmed: 24477317
BMJ Open. 2020 Jul 20;10(7):e039334
pubmed: 32690752
World J Urol. 2017 Dec;35(12):1863-1869
pubmed: 28685181
J Oncol Pract. 2015 Jan;11(1):e66-74
pubmed: 25466708
Psychooncology. 2015 Mar;24(3):348-54
pubmed: 25138075
JCO Oncol Pract. 2020 Sep;16(9):527-529
pubmed: 32401684
Eur Urol. 2015 Oct;68(4):729-35
pubmed: 25900782
BMC Fam Pract. 2010 Aug 28;11:61
pubmed: 20799981
PLoS One. 2015 Jun 08;10(6):e0129282
pubmed: 26052944
J Oncol Pract. 2010 Nov;6(6):e5-e10
pubmed: 21358951
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Cochrane Database Syst Rev. 2019 Sep 03;9:CD011462
pubmed: 31476800
J Gen Intern Med. 2020 Aug;35(8):2296-2303
pubmed: 32472486
Eur Urol. 2020 Sep;78(3):301-303
pubmed: 32334884
JMIR Med Educ. 2016 Jul 08;2(2):e11
pubmed: 27731865
J Telemed Telecare. 2015 Sep;21(6):323-30
pubmed: 25995331
Eur Urol. 2020 Dec;78(6):786-811
pubmed: 32616405
Eur Urol. 2020 Jul;78(1):29-42
pubmed: 32414626
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Hernia. 2020 Feb;24(1):179-185
pubmed: 31542838
J Arthroplasty. 2019 Oct;34(10):2253-2259
pubmed: 31128890
Br J Cancer. 2018 May;118(10):1399-1405
pubmed: 29593338
PLoS One. 2020 Mar 23;15(3):e0230417
pubmed: 32203532
Urol Oncol. 2020 Jun;38(6):603.e17-603.e25
pubmed: 32253117
Eur Urol. 2020 Aug;78(2):276-280
pubmed: 32534910
Internet Interv. 2017 Jun 15;9:57-64
pubmed: 30135838
Eur Urol. 2018 Oct;74(4):531-534
pubmed: 29793815
Cancer. 2020 Feb 1;126(3):506-514
pubmed: 31742674
Diagnostics (Basel). 2017 Oct 17;7(4):
pubmed: 29039744
World J Urol. 2020 Oct;38(10):2547-2554
pubmed: 31893313
JAMA. 2020 Jan 14;323(2):140-148
pubmed: 31935026
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
N Engl J Med. 2019 May 16;380(20):1891-1893
pubmed: 31091371
J Urol. 2003 Aug;170(2 Pt 1):438-41
pubmed: 12853794
Eur Urol. 2018 Aug;74(2):157-164
pubmed: 29625756
Can Urol Assoc J. 2021 Jan;15(1):E1-E5
pubmed: 32701439
J Urol. 2016 May;195(5):1362-1367
pubmed: 26682758
J Urol. 2019 May;201(5):902-908
pubmed: 30694938
BMC Health Serv Res. 2020 Jan 31;20(1):73
pubmed: 32005232
Eur Urol. 2020 Jul;78(1):e27-e35
pubmed: 32345523
J Gerontol A Biol Sci Med Sci. 2005 Aug;60(8):1035-8
pubmed: 16127109
Urologe A. 2018 Feb;57(2):164-171
pubmed: 29209755
BMC Urol. 2020 Feb 11;20(1):12
pubmed: 32046687
Int J Behav Nutr Phys Act. 2018 Jun 7;15(1):49
pubmed: 29880049
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
Eur Urol. 2015 Sep;68(3):408-15
pubmed: 25698065
Eur Urol. 2020 Jul;78(1):11-15
pubmed: 32307215
JCO Oncol Pract. 2020 Jul;16(7):363-368
pubmed: 32421390
Br J Cancer. 2019 Apr;120(8):840-847
pubmed: 30837680
J Urol. 2020 Sep;204(3):442-449
pubmed: 32191580
Eur Urol. 2020 Aug;78(2):265-275
pubmed: 32507625
BMJ. 1998 Jun 13;316(7147):1796-801
pubmed: 9624070
J Med Internet Res. 2019 Jun 2;21(6):e14094
pubmed: 31199294
Can Urol Assoc J. 2017 Aug;11(8):270-274
pubmed: 28798830
Eur J Oncol Nurs. 2013 Apr;17(2):162-9
pubmed: 22608878
Telemed J E Health. 2019 Dec;25(12):1231-1236
pubmed: 30758247
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
J Clin Oncol. 2015 Jan 20;33(3):272-7
pubmed: 25512465
Lancet Oncol. 2020 Jun;21(6):748-750
pubmed: 32359404
J Clin Oncol. 2017 Jul 10;35(20):2299-2305
pubmed: 28410011
Eur Urol. 2020 Jul;78(1):21-28
pubmed: 32376137
J Clin Oncol. 2015 Dec 10;33(35):4151-7
pubmed: 26351352
J Glob Oncol. 2016 Aug 10;3(3):242-249
pubmed: 28717766
Br J Surg. 2020 Sep;107(10):1250-1261
pubmed: 32350857
BJU Int. 2017 Dec;120(6):755-765
pubmed: 29168333
Eur Urol. 2020 Jul;78(1):1-3
pubmed: 32349928
Eur Urol Focus. 2020 May 15;6(3):437-439
pubmed: 31874796